Table 1 Baseline value of novel markers by outcome group in patients with BRVO treated with aflibercept
Need of additional aflibercept after loading | Macular edema at month 12 | Improvement of 10 or more ETDRS letters from baseline | ||||
|---|---|---|---|---|---|---|
No | Yes | No | Yes | No | Yes | |
n | 10 | 31 | 26 | 15 | 13 | 28 |
Retinal oximetry (n = 33) | ||||||
Arteriolar saturation (%) | 99.8 ± 9.0 | 92.3 ± 10.1 | 96.8 ± 10.8 | 90.0 ± 8.0 | 90.7 ± 9.3 | 95.9 ± 10.4 |
Venular saturation (%) | 53.5 ± 14.2 | 52.3 ± 16.9 | 55.9 ± 13.7 | 47.6 ± 18.5 | 54.7 ± 12.4 | 51.7 ± 17.5 |
OCT-A, SCP | ||||||
Area of FAZ (mm2) (n = 20) | 0.28 ± 0.12 | 0.31 ± 0.16 | 0.36 ± 0.17 | 0.24 ± 0.08 | 0.28 ± 0.11 | 0.32 ± 0.17 |
Area of non-perfusion (mm2) (n = 27) | 4.43 ± 1.07 | 4.48 ± 1.36 | 4.53 ± 1.06 | 4.35 ± 1.69 | 4.55 ± 1.42 | 4.43 ± 1.23 |
Vessel density (%) (n = 27) | 73.8 ± 6.7 | 73.2 ± 8.7 | 73.2 ± 6.5 | 73.7 ± 11.1 | 72.8 ± 9.7 | 73.7 ± 7.4 |
Fractal dimension (n = 27) | 1.68 ± 0.01 | 1.68 ± 0.02 | 1.68 ± 0.01 | 1.68 ± 0.02 | 1.68 ± 0.02 | 1.68 ± 0.01 |
Microperimetry (n = 39) | ||||||
Mean retinal sensitivity (dB) | 22.6 ± 3.4 | 20.9 ± 4.2 | 21.3 ± 4.1 | 21.3 ± 4.1 | 22.5 ± 4.4 | 20.8 ± 3.9 |